Bicara Therapeutics (BCAX) Retained Earnings (2023 - 2026)

Bicara Therapeutics' Retained Earnings history runs 4 years deep, the most recent figure standing at -$243000.0 for Q1 2026.

• On a quarterly basis, Retained Earnings rose 99.91% year-over-year to -$243000.0 in Q1 2026; TTM through Mar 2026 was -$243000.0, a 99.91% increase from a year earlier, with the FY2025 full-year figure at -$359.0 million, down 62.42% from the prior year.
• Retained Earnings rose to -$243000.0 in Q1 2026 per BCAX's latest filing, from -$359.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$243000.0 in Q1 2026 and bottomed at -$359.0 million in Q4 2025.
• The 4-year median for Retained Earnings is -$239.5 million (2025), against an average of -$224.8 million.
• Across the five-year window, Retained Earnings tumbled 62.42% in 2025 and surged 99.91% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$153.0 million in 2023, then tumbled by 44.44% to -$221.0 million in 2024, then tumbled by 62.42% to -$359.0 million in 2025, then soared by 99.93% to -$243000.0 in 2026.
• Per Business Quant, the three latest BCAX Retained Earnings figures stand at -$243000.0 (Q1 2026), -$359.0 million (Q4 2025), and -$321.6 million (Q3 2025).